{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:05:26Z","timestamp":1784696726524,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.dld.2025.09.032","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T02:46:12Z","timestamp":1761619572000},"page":"2321-2330","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Relapse rate following withdrawal of vedolizumab and ustekinumab in patients with inflammatory bowel disease - a multicenter retrospective controlled study. The VEDUST-EXIT Study"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8962-4263","authenticated-orcid":false,"given":"Ahmad","family":"Albshesh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Kucha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Pugliese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6676-1222","authenticated-orcid":false,"given":"Aur\u00e9lien","family":"Amiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein","family":"Mahajna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Eder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3187-2894","authenticated-orcid":false,"given":"Edoardo Vincenzo","family":"Savarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Vavricka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Castiglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3230-6832","authenticated-orcid":false,"given":"Nicola","family":"Imperatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeljko","family":"Krznaric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaya Mushka","family":"Abitbol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Or","family":"Hen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3879-9722","authenticated-orcid":false,"given":"Marta","family":"Zaborowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Carbonnel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8766-5108","authenticated-orcid":false,"given":"Giuseppe","family":"Cuccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9378-2117","authenticated-orcid":false,"given":"Greta","family":"Lorenzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eran","family":"Zittan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3488-2593","authenticated-orcid":false,"given":"Edyta","family":"Zag\u00f3rowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2468-7292","authenticated-orcid":false,"given":"Daria","family":"Maniero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shomron","family":"Ben-Horin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uri","family":"Kopylov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.dld.2025.09.032_bib0001","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.dld.2025.09.032_bib0002","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1053\/j.gastro.2015.08.055","article-title":"Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease","volume":"149","author":"Torres","year":"2015","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.dld.2025.09.032_bib0003","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1053\/j.gastro.2018.04.012","article-title":"Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases","volume":"155","author":"Kirchgesner","year":"2018","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.dld.2025.09.032_bib0004","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1053\/j.gastro.2011.09.034","article-title":"Maintenance of remission among patients with Crohn\u2019s disease on antimetabolite therapy after infliximab therapy is stopped","volume":"142","author":"Louis","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2025.09.032_bib0005","first-page":"1","article-title":"Withdrawal of anti-tumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU","author":"Gisbert","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.dld.2025.09.032_bib0006","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/ajg.2016.54","article-title":"The risk of relapse after anti-TNF discontinuation in inflammatory bowel disease: systematic review and meta-analysis","volume":"111","author":"Gisbert","year":"2016","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.dld.2025.09.032_bib0007","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S2468-1253(22)00385-5","article-title":"Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn\u2019s disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial","volume":"8","author":"Louis","year":"2023","journal-title":"lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.dld.2025.09.032_bib0008","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/gutjnl-2024-333385","article-title":"Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU","volume":"74","author":"Gisbert","year":"2025","journal-title":"Gut"},{"issue":"20","key":"10.1016\/j.dld.2025.09.032_bib0009","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s Disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.dld.2025.09.032_bib0010","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.dld.2025.09.032_bib0011","first-page":"697","article-title":"Association of vedolizumab level, anti-drug antibodies, and \u03b14\u03b27 occupancy with response in patients with inflammatory bowel diseases","volume":"16","author":"Ungar","year":"2018","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"issue":"10","key":"10.1016\/j.dld.2025.09.032_bib0012","first-page":"2244","article-title":"Ustekinumab pharmacokinetics and exposure response in a phase 3 randomized trial of patients with ulcerative colitis","volume":"18","author":"Adedokun","year":"2020","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"issue":"5","key":"10.1016\/j.dld.2025.09.032_bib0013","doi-asserted-by":"crossref","first-page":"518","DOI":"10.3109\/00365521.2012.660541","article-title":"Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study","volume":"47","author":"Steenholdt","year":"2012","journal-title":"Scand J Gastroenterol"},{"issue":"9","key":"10.1016\/j.dld.2025.09.032_bib0014","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/j.1365-2036.2010.04446.x","article-title":"Maintenance of clinical benefit in Crohn\u2019s disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort","volume":"32","author":"Waugh","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.dld.2025.09.032_bib0015","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/apt.16182","article-title":"Systematic review with meta-analysis: the effects of immunomodulator or biological withdrawal from mono- or combination therapy in inflammatory bowel disease","volume":"53","author":"Dohos","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.dld.2025.09.032_bib0016","first-page":"1671","article-title":"Prediction of relapse after anti-tumor necrosis factor cessation in Crohn\u2019s Disease: individual participant data meta-analysis of 1317 patients from 14 studies","volume":"20","author":"Pauwels","year":"2022","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"issue":"1","key":"10.1016\/j.dld.2025.09.032_bib0017","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/ecco-jcc\/jjx101","article-title":"European Crohn\u2019s and Colitis Organisation topical review on treatment withdrawal [\u2019Exit Strategies\u2019] in inflammatory bowel disease","volume":"12","author":"Doherty","year":"2018","journal-title":"J Crohns Colitis"},{"issue":"10080","key":"10.1016\/j.dld.2025.09.032_bib0018","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Peyrin-Biroulet L, Colombel J-F. Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.dld.2025.09.032_bib0019","article-title":"The efficacy of currently licensed biologics for treatment of ulcerative colitis: a literature review","volume":"15","author":"Awan","year":"2023","journal-title":"Cureus"},{"issue":"10","key":"10.1016\/j.dld.2025.09.032_bib0020","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/ecco-jcc\/jjae063","article-title":"Real-world comparison of the effectiveness between Ustekinumab and Vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent","volume":"18","author":"Fumery","year":"2024","journal-title":"J Crohns Colitis"},{"issue":"7","key":"10.1016\/j.dld.2025.09.032_bib0021","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/ecco-jcc\/jjaa005","article-title":"Maintenance of remission among patients with inflammatory bowel disease after Vedolizumab discontinuation: a multicentre cohort study","volume":"14","author":"Martin","year":"2020","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2025.09.032_bib0022","doi-asserted-by":"crossref","DOI":"10.1177\/17562848231151295","article-title":"Real-world outcomes of 54-week vedolizumab therapy and response durability after treatment discontinuation in ulcerative colitis: results from a multicenter prospective POLONEZ study","volume":"16","author":"Eder","year":"2023","journal-title":"Therap Adv Gastroenterol"},{"issue":"6","key":"10.1016\/j.dld.2025.09.032_bib0023","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.3390\/jcm14061793","article-title":"Relapse rates and predictors for Relapse in ulcerative colitis and Crohn's Disease patients after discontinuation of Vedolizumab or Ustekinumab: the REVEUS study","volume":"14","author":"Massano","year":"2025","journal-title":"J Clin Med"},{"issue":"10114","key":"10.1016\/j.dld.2025.09.032_bib0024","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","article-title":"Effect of tight control management on Crohn\u2019s disease (CALM): a multicentre, randomised, controlled phase 3 trial","volume":"390","author":"Colombel","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.dld.2025.09.032_bib0025","first-page":"22","article-title":"Withdrawal of immunomodulators or TNF antagonists in patients with inflammatory bowel diseases in remission on combination therapy: a systematic review and meta-analysis","volume":"22","author":"Katibian","year":"2024","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"issue":"3","key":"10.1016\/j.dld.2025.09.032_bib0026","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.3748\/wjg.v22.i3.1017","article-title":"How to predict clinical relapse in inflammatory bowel disease patients","volume":"22","author":"Liverani","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10.1016\/j.dld.2025.09.032_bib0027","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1080\/00365521.2019.1582693","article-title":"Relapse rates and predictors for relapse in a real-life cohort of IBD patients after discontinuation of anti-TNF therapy","volume":"54","author":"Bots","year":"2019","journal-title":"Scand J Gastroenterol"},{"issue":"6","key":"10.1016\/j.dld.2025.09.032_bib0028","first-page":"1021","article-title":"Outcome after discontinuation of TNF\u03b1-blocking therapy in patients with inflammatory bowel disease in deep remission","volume":"20","author":"Molander","year":"2014","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"10.1016\/j.dld.2025.09.032_bib0029","first-page":"1456","article-title":"Outcome of elective withdrawal of anti-tumour necrosis factor-\u03b1 therapy in patients with Crohn\u2019s disease in established remission","volume":"11","author":"Brooks","year":"2017","journal-title":"J Crohns Colitis"},{"issue":"7","key":"10.1016\/j.dld.2025.09.032_bib0030","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/ecco-jcc\/jjaa005","article-title":"Maintenance of remission among patients with inflammatory bowel disease after vedolizumab discontinuation: a multicentre cohort study","volume":"14","author":"Martin","year":"2020","journal-title":"J Crohn\u2019s Colitis"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865825011466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865825011466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T14:24:57Z","timestamp":1766154297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865825011466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1590865825011466"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2025.09.032","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relapse rate following withdrawal of vedolizumab and ustekinumab in patients with inflammatory bowel disease - a multicenter retrospective controlled study. The VEDUST-EXIT Study","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2025.09.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}